Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
J Am Soc Cytopathol. 2022 Nov-Dec;11(6):403-414. doi: 10.1016/j.jasc.2022.08.002. Epub 2022 Aug 19.
Ancillary and molecular testing of cytopathology specimens has emerged as a reliable and useful tool to provide diagnostic information and treatment-related biomarker status for the management of cancer patients. The cytology specimens obtained through minimally invasive means have proven suitable testing substrates for a variety of ancillary tests, including immunohistochemistry, fluorescence in situ hybridization, as well as polymerase chain reaction and next generation sequencing molecular techniques. By focusing specifically on the cytology specimen, this review provides an overview of basic testing considerations and assay selection in addition to updates on the ancillary testing of cytologic tumor specimens from the lung, salivary gland, and thyroid.
细胞病理学标本的辅助和分子检测已成为提供诊断信息和治疗相关生物标志物状态的可靠且有用的工具,以用于癌症患者的管理。通过微创手段获得的细胞学标本已被证明是各种辅助检测的合适检测基质,包括免疫组织化学、荧光原位杂交以及聚合酶链反应和下一代测序分子技术。通过专门关注细胞学标本,本综述除了提供有关肺、唾液腺和甲状腺细胞肿瘤标本的辅助检测的最新信息外,还概述了基本检测考虑因素和检测选择。